CAMKK2 and Alzheimer disease: In this study, we demonstrated that CP-AMPAR antagonist IEM1460 and CaMKK inhibitor STO 609 significantly enhanced γ oscillations, IEM1460 and STO 609 alone or in combination may therefore serve as one potentially therapeutic strategy for the AD treatment.